Lonza using energy broker to cut costs at production sites

Related tags Biology Biotechnology

Lonza is working with energy broker Usource to reduce costs at a number of its US production and R&D facilities.

Usource will assess all electricity and natural gas suppliers using proprietary transaction and market monitoring systems to lower energy costs at Lonza sites in seven US states. Savings are realised by monitoring and creating competition among natural gas and electricity suppliers.

By understanding these markets and timing solicitations, Usource has already taken some of Lonza's electricity and natural gas requirements to market and locked up considerable savings​”, said Bill Kibler, business development director at Usource.

Production, research and development (R&D), and sales sites in New Hampshire, Maine, Illinois, Massachusetts, Pennsylvania, Maryland and Texas are included in the deal. Lonza’s New Jersey headquarters in excluded from the agreement.

Each site presents a “very different challenge​” to Usource, said Kibler. Activities at the facilities range from office work to biopharmaceutical process development and manufacturing.

New branding

Lonza is rebranding and focusing on its seven main markets to better reflect the business and client needs.

Understanding the needs of our customers, Lonza business units will no longer communicate singly with our diverse customer base, but instead present a coordinated and unified approach, demonstrating all that Lonza can offer them​”, reads the press statement.

Lonza’s main markets are: Bio Research; Pharma & Biotech; Agriculture; Nutrition; Microbial Control; Materials Science; and Personal Care. Each of these markets is served by one or more of the business units, life sciences ingredients, custom manufacturing and bioscience, at Lonza.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars